semaj83/ctmatch_classification huggingface dataset:
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Osteoarthritis Meets the American College of Rheumatology for OA Radiographic evidence of OA affecting one or both knees Complaints of chronic knee pain (pain on most days for at least 6 months prior to study entry) No other major weight-bearing joint affected by OA  Any significant medical condition or disease that would make study participation unsafe or increase the risk of a significant adverse experience during the course of the study (e.g., myocardial infarction in the 6 months prior to study entry) Currently involved in a regular exercise program An abnormal cardiac response to exercise, such as exercise-induced BT or an abnormal blood pressure response A body mass index (BMI) greater than 42 A non-OA inflammatory arthropathy Currently using oral corticosteroids on a regular basis Anticipate to have a knee surgery in the next 18 months (or before the anticipated date of their study completion) Knee surgery (arthroscopic or knee replacement) within a year of enrollment Intraarticular steroid or hyaluronan knee injections in one of both knees within 3 months of enrollment
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Focal Dystonia Focal Dystonia Subjects must be Right hand dominant Between 18 and 65 years old Diagnosed with mild, simple focal hand dystonia. For this study mild, simple focal hand dystonia suggests that the patient does not present symptoms when performing tasks other than writing. Additionally, the patient should be able to write for 20 seconds consecutively Willing to abstain from alcohol 48 hours prior to the study Volunteers must be Healthy right-handed dominant individuals Between 18 and 65 years old Willing to abstain from alcohol 48 hours prior to the study  Subjects with implanted devices such as pacemakers, medication pumps or defibrillators, metal in the cranium except mouth, intracardiac lines, history of shrapnel injury or any other condition/device that may be contraindicated or prevent the acquisition of MRI Subjects with any finding on the MRI safety questionnaire which prevents them from safely undergoing an MRI scan Subjects who are pregnant Subjects with claustrophobia or other restrictions which prevent them from undergoing a scan in a confined space for up to 60 minutes Subjects with any visual, motor, or hearing difficulties Subjects with severe focal hand dystonia i.e., subjects who experience dystonic spasms in tasks other than/in addition to writing Subjects with mirror dystonia Subjects without the capacity to give consent Subjects with any history of a severe medical condition, such as cardiovascular disease, which will prevent them from lying flat for up to 60 minutes Subjects with any history of brain tumor, stroke, head trauma or vascular malformation as obtained by history or from imaging studies
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia Chronic Kidney Disease Chronic Renal Failure Pure Red Cell Aplasia Participants who have confirmed antibody-mediated Pure red cell aplasia (PRCA) are potentially eligible for enrollment into this study Participants must be ≥ 18 years old at the time of consent Erythropoiesis stimulating agents (ESAs) must be discontinued for a minimum of 1 month prior to screening Participant requires periodic transfusions to maintain hemoglobin Hemoglobin < 10 g/dL for at least 2 measurements or participant has received a transfusion within the past 4 weeks to achieve a hemoglobin > 10 g/dL Confirmation that an anti-erythropoietin antibody sample was obtained for analysis by the central reference laboratory within 1 month prior to baseline Participants can either be participants with chronic kidney disease not yet requiring renal replacement therapy (participants not on dialysis), those on regular hemodialysis or peritoneal dialysis, or following a renal transplant Participants may or may not have previously been treated with immunosuppressive therapy Pre-menopausal females (with the exception of those who are surgically sterile) must have a negative pregnancy test at screening Written informed consent must be obtained  Participants already successfully on another erythropoietic agent Abnormal bone marrow findings consistent with the diagnosis of myelodysplasia, a myeloproliferative disorder, hematologic malignancy or evidence of metastatic infiltration Poorly controlled hypertension Previous exposure to any investigational agent within 4 weeks prior to administration of study drug or planned receipt during the study period High likelihood of early withdrawal or interruption of the study Participants who refuse to give informed consent Women who are pregnant, lactating or not using a medically approved birth control Life expectancy <12 months
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Chagas Cardiomyopathy Chronic Heart Failure Males or females aged 18 to 70 years Heart failure symptoms NYHA functional class II to IV Left ventricular ejection fraction <40% determined by bi-dimensional echocardiography using modified Simpson's rule for ventricular volumes Subjects must be on standard and stable outpatient doses of ACEIs or angiotensin II receptor antagonist for at least four weeks Subjects receiving diuretics must be on a stable dose for at least two weeks Clinical Euvolemia:as evidenced by absence of rales, no pleural effusion or ascitis and no more than minimal peripheric edema  CHF due to ischemic heart disease, valvular disease or any other etiology different than CD Severe aortic insufficiency Baseline advanced AV block defined as Mobitz type 2 or third degree AV block Serum creatinine >2.5 mg/dl Resting Heart rate less < 45 bpm Known malignancy and other severe disease which shorten life expectancy < 6 months Subjects with contraindications for beta-blockers: severe obstructive chronic pulmonary disease, asthma, severe pulmonary hypertension, type 1 diabetes mellitus or history of hypoglicemia Suspected or confirmed chronic infectious disease including HIV and hepatitis B History of active substance or alcohol abuse within the last year Clinically significant psychiatric illness which can negatively affect the subject compliance and participation in the trial
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 3.0-8.0,  Autism Pervasive Developmental Disorder Ages 3-8 years Diagnosis of autism spectrum disorder Serum copper/zinc ratio greater than 2.0 or as determined in phase 1 of the study  Known chromosomal disorder or neurological disorders other than autism
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Aging A)Participants must be at least 60 years old B)Participants must have a Mini-Mental State Exam (MMSE) score of 24 or higher to ensure that participants do not meet common for dementia C)Participants must be a native English speaker D)Participants must be able to see well enough to read the consent form E)Participants must be able to hear well enough to understand ordinary spoken conversation when the clinical specialist holds a paper in front of his or her face to prevent the participant from lip-reading. F)Participants must be willing to commit to the time requirements of the study and not have any scheduled trips or absences for more than 1 week during the training  A)Participants must not be planning to begin cholinesterase inhibitor (AChEI) therapy or to change their dosing levels. Subjects currently using AChEI will be included if they have an established steady dosing history at least one month prior to the study and are expected to continue at the same dosage throughout the study. B)Participants must not have had a head trauma that caused them to lose consciousness in the past five years and have had no subsequent symptoms. C)Participants must not have had a stroke within the past year; or have had a stroke that has left them with expressive or receptive language problems. D)Participants must not have any central nervous system disorder that could contribute to cognitive impairment. E)Participants must not have a tremor preventing the use of a computer mouse or other pointing device. F)Participants must not currently be active in another clinical trial
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Aging A)Participants must be at least 60 years old B)Participants must have a Mini-Mental State Exam (MMSE) score of 24 or higher to ensure that participants do not meet common for dementia C)Participants must be a native English speaker D)Participants must be able to see well enough to read the consent form E)Participants must be able to hear well enough to understand ordinary spoken conversation in a slightly noisy room F)Participants must be willing to commit to the time requirements of the study and not have any scheduled trips or absences for more than 1 week during the training  A)Participants must not be planning to begin cholinesterase inhibitor (AChEI) therapy or to change their dosing levels. Subjects currently using AChEI will be included if they have an established steady dosing history at least one month prior to the study and are expected to continue at the same dosage throughout the study. B)Participants must not have had a head trauma that caused them to lose consciousness. C)Participants must not have had a stroke within the past year; or have had a stroke that has left them with expressive or receptive language problems. D)Participants must not have any central nervous system disorder that could contribute to cognitive impairment. E)Participants must not have a tremor preventing the use of a computer mouse or other pointing device. F)Participants must not currently be active in another clinical trial
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rosacea Diagnosis of facial rosacea made or confirmed by one of the investigators Severity of signs of rosacea "greater than mild" at the time of enrollment  Treatment for rosacea during the 3 months prior to enrollment Use of zinc dietary supplement > 25 mg per day during the 3 months prior to enrollment ( Most patients taking multivitamins with Zinc, often 15 mg per day, will not be excluded, whereas most patients taking additional Zinc supplements, often 25-50 mg per day or more will be excluded.) Diagnosis of rosacea fulminancy Pregnant or breast feeding
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Aged Veteran with completed Geriatrics and Extended Care Referral Form in data base at study site  Inability to complete telephone interview
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Cancer Patients with suspicion of non-invasive bladder cancer indicated for a transuretheral resection of the bladder Above 18 years Written informed consent obtained  Gross hematuria. (Note: Gross hematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded if in the investigator's opinion, rinsing during cystoscopy will alleviate the possible interference with fluorescence cystoscopy) Patient with porphyria Known allergy to hexyl aminolevulinate hydrochloride or a similar compound Participation in other clinical studies with investigational drugs either concurrently or within the last 30 days Pregnant or breast-feeding (all women of child-bearing potential must document a negative serum or urine pregnancy test at screening and use the contraceptive pill or intrauterine device (IUD) during the treatments and for at least one month thereafter) Conditions associated with a risk of poor protocol compliance
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Prosthesis ages 18-60 years old Control group: normal, healthy volunteers Amputee group: unilateral, transradial myoelectric prosthesis users  elderly > 60 children < 18 pregnant women persons with shoulder impairments, injuries, or problems bilateral upper limb amputees
Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Healthy Cholecystectomized Male or female from 18-60 years of age, cholecystectomized at least 4 months prior to the start of the study In a good health as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests at screening Body mass index within 19-29 kg/m2 Able to communicate well with the investigator and comply with the requirements of the study  Any clinically significant abnormal laboratory values at screening, or evidence of clinically significant abnormal findings at the physical exam at screening, or significant illness within 2 weeks prior to dosing A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated) History of clinically significant drug allergy, history of atopic allergy, history or clinical evidence of pancreatic injury or pancreatitis, clinical evidence of liver disease or liver injury , history or presence of impaired renal function, or history of urinary obstruction or difficulty urinating History of immunocompromise, including a positive HIV Known positive hepatitis B or C surface antigen (HBsAg) or Hepatitis C test result (anti-HCV) History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays at screening Female subjects who are pregnant or lactating, or are of childbearing potential and without a medically acceptable and highly effective method for birth control Demonstrating intolerance to octreotide at baseline Any subject who has a known history of diabetes mellitus in parents or grandparents. Other protocol-defined inclusion/